Oncolytics Biotech Changes Auditor to Baker Tilly Amidst Corporate Restructuring
ONCY is trading near its 52-week low of $0.77 (3.8% above the low).
Summary
Oncolytics Biotech has appointed Baker Tilly US, LLP as its new independent registered public accounting firm, replacing Ernst & Young LLP, citing a corporate restructuring. The company confirmed there were no disagreements with the former auditor.
Key Events · Corporate Governance and Compliance · ONCY
-
Auditor Change Announced
Oncolytics Biotech Inc. has engaged Baker Tilly US, LLP as its new independent registered public accounting firm, replacing Ernst & Young LLP, effective July 6, 2026.
-
Reason for Change: Corporate Restructuring
The company stated the change was due to a corporate restructuring.
-
No Disagreements with Former Auditor
The company confirmed there were no disagreements with Ernst & Young LLP on accounting principles, financial disclosures, or auditing procedures. Ernst & Young also confirmed this.
-
No Reportable Events
There were no reportable events during the fiscal years 2024, 2025, or the subsequent period through the date of change.
Analysis · ONCY · Life Sciences
This 8-K reports a change in the company's independent auditor from Ernst & Young LLP to Baker Tilly US, LLP. While auditor changes can sometimes signal underlying financial issues, the company explicitly states this change is due to "corporate restructuring" and, importantly, confirms there were no disagreements on accounting principles or practices, nor any reportable events with the outgoing auditor. The previous auditor's reports did include a "going concern" explanatory paragraph, which is consistent with prior disclosures and not new information. This change is notable as it affects a key oversight function, but the disclosed reasons mitigate immediate concerns about financial integrity.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 29.4% of the 2797 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ONCY was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $94.6M. The 52-week trading range was $0.77 to $1.51. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.